Collaboration - August 6, 2015
Sprint Bioscience enters into collaboration with Bayer HealthCare
Sprint Bioscience AB and Bayer HealthCare have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates. Under the agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer. Subsequently, Bayer will have full control over further development and worldwide commercialization rights for potential cancer therapeutics […]
Acquisition - December 10, 2013
Moberg Pharma acquires OTC brands in the US from Bayer HealthCare
Moberg Pharma has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources. The acquired portfolio includes Domeboro®, a topical […]
